U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07753603) titled 'Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)' on Aug. 03.
Brief Summary: The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
Study Start Date: Aug. 04
Study Type: INTERVENTIONAL
Condition:
Thyroid Eye Disease, TED
Graves Orbitopathy
Intervention:
DRUG: linsitinib
150 mg linsitinib is taken twice daily by mouth for 24 weeks
DRUG: Placebo
0 mg placebo taken twice daily by mouth for 24 weeks
Recruitment Status: RECRUITING
Sponsor: Sling Therapeutics, Inc.
Pu...